Strategies to optimise propofol-opioid anaesthesia

Clinical Pharmacokinetics

Volumn 43, Issue 9, 2004, Pages 577-593

  Lichtenbelt, Bart Jan ^a   Mertens, Martijn ^a   Vuyk, Jaap ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ETOMIDATE; FENTANYL; METHOHEXITAL; OPIATE; PROPOFOL; REMIFENTANIL; SUFENTANIL;

ANESTHESIA; BISPECTRAL INDEX; BLOOD BRAIN BARRIER; BRADYCARDIA; COMPUTER SIMULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG MEGADOSE; DRUG OXIDATION; DRUG PENETRATION; DRUG POTENTIATION; HEART OUTPUT; HEMODYNAMICS; HUMAN; LOW DRUG DOSE; MUSCLE RIGIDITY; NAUSEA; PRIORITY JOURNAL; PRURITUS; RESPIRATION DEPRESSION; RESPIRATORY FUNCTION; REVIEW; SIDE EFFECT; SYMPATHETIC TONE; VOMITING;

ANESTHESIA; ANESTHETICS, INTRAVENOUS; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; HUMANS; NARCOTICS; PROPOFOL;

EID: 3242713853     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200443090-00002     Document Type: Review

References (76)

1. Kuipers JA, Boer F, de Roode A, et al. Modeling population pharmacokinetics of lidocaine: should cardiac output be included as a patient factor? Anesthesiology 2001; 94 (4): 566-73
2. Kuipers JA, Boer F, Olofsen E, et al. Recirculatory and compartmental pharmacokinetic modeling of alfentanil in pigs: the influence of cardiac output. Anesthesiology 1999; 90 (4): 1146-57
3. Kuipers JA, Boer F, Olofsen E, et al. Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients: the influence of cardiac output. Anesthesiology 2001; 94 (1): 47-55
4. Kharasch ED, Jubert C, Senn T, et al. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. J Clin Pharmacol 1999; 39 (7): 664-9
5. Labroo RB, Paine MF, Thummel KE, et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 1997; 25 (9): 1072-80
6. van den Nieuwenhuyzen MC, Engbers FH, Burm AG, et al. Target-controlled infusion of alfentanil for postoperative analgesia: contribution of plasma protein binding to intra-patient and inter-patient variability. Br J Anaesth 1999; 82 (4): 580-5
7. Mertens MJ, Vuyk J, Olofsen E, et al. Propofol alters the pharmacokinetics of alfentanil in healthy male volunteers. Anesthesiology 2001; 94 (6): 949-57
8. 95 propofol-opioid concentrations that assure adequate anesthesia and a rapid return of consciousness. Anesthesiology 1997; 87 (6): 1549-62
9. Kanto J, Gepts E. Pharmacokinetic implications for the clinical use of propofol. Clin Pharmacokinet 1989; 17 (5): 308-26
10. 50 of propofol for loss of consciousness and skin incision. Anesthesiology 1994; 81 (4): 820-8
11. Stanski DR, Shafer SL. Quantifying anesthetic drug interaction: implications for drug dosing. Anesthesiology 1995; 83 (1): 1-5
12. Vuyk J, Lim T, Engbers FH, et al. The pharmacodynamic interaction of propofol and alfentanil during lower abdominal surgery in women. Anesthesiology 1995; 83 (1): 8-22
13. Schnider TW, Minto CF, Gambus PL, et al. The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology 1998; 88 (5): 1170-82
14. Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age: a simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987; 240 (1): 159-66
15. Minto CF, Schnider TW, Shafer SL. Pharmacokinetics and pharmacodynamics of remifentanil (II): model application. Anesthesiology 1997; 86 (1): 24-33
16. Maitre PO, Vozeh S, Heykants J, et al. Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients. Anesthesiology 1987; 66 (1): 3-12
17. Gepts E, Shafer SL, Camu F, et al. Linearity of pharmacokinetics and model estimation of sufentanil. Anesthesiology 1995; 83 (6): 1194-204
18. Vuyk J, Engbers FH, Burm AG, et al. Pharmacodynamic interaction between propofol and alfentanil when given for induction of anesthesia. Anesthesiology 1996; 84 (2): 288-99
19. Schnider TW, Minto CF, Shafer SL, et al. The influence of age on propofol pharmacodynamics. Anesthesiology 1999; 90 (6): 1502-16
20. Saint-Maurice C, Cockshott ID, Douglas EJ, et al. Pharmacokinetics of propofol in young children after a single dose. Br J Anaesth 1989; 63 (6): 667-70
21. Kirkpatrick T, Cockshott ID, Douglas EJ, et al. Pharmacokinetics of propofol (Diprivan) in elderly patients. Br J Anaesth 1988; 60 (2): 146-50
22. Schüttler J, Ihmsen H. Population pharmacokinetics of propofol: a multicenter study. Anesthesiology 2000; 92 (3): 727-38
23. Vuyk J, Oostwouder CJ, Vletter AA, et al. Gender differences in the pharmacokinetics of propofol in elderly patients during and after continuous infusion. Br J Anaesth 2001; 86 (2): 183-8
24. Oda Y, Hamaoka N, Hiroi T, et al. Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol 2001; 51 (3): 281-5
25. Guitton J, Buronfosse T, Desage M, et al. Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth 1998; 80 (6): 788-95
26. McKillop D, Wild MJ, Butters CJ, et al. Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica 1998; 28 (9): 845-53
27. Ebert TJ, Muzi M, Berens R, et al. Sympathetic responses to induction of anesthesia in humans with propofol or etomidate. Anesthesiology 1992; 76 (5): 725-33
28. Sztark F, Ichas F, Mazat JP, et al. Propofol and cellular calcium homeostasis [letter]. Anesthesiology 1995; 83 (6): 1386
29. Li YC, Ridefelt P, Wiklund L, et al. Propofol induces a lowering of free cytosolic calcium in myocardial cells. Acta Anaesthesiol Scand 1997; 41 (5): 633-8
30. Nieuwenhuijs D, Sarton E, Teppema L, et al. Propofol for monitored anesthesia care: implications on hypoxic control of cardiorespiratory responses. Anesthesiology 2000; 92 (1): 46-54
31. Nieuwenhuijs D, Sarton E, Teppema LJ, et al. Respiratory sites of action of propofol: absence of depression of peripheral chemoreflex loop by low-dose propofol. Anesthesiology 2001; 95 (4): 889-95
32. Kapila A, Glass PS, Jacobs JR, et al. Measured context-sensitive half-times of remifentanil and alfentanil. Anesthesiology 1995; 83 (5): 968-75
33. Westmoreland CL, Hoke JF, Sebel PS, et al. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology 1993; 79 (5): 893-903
34. Dershwitz M, Hoke JF, Rosow CE, et al. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology 1996; 84 (4): 812-20
35. Hoke JF, Shlugman D, Dershwitz M, et al. Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers. Anesthesiology 1997; 87 (3): 533-41
36. Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil (I): model development. Anesthesiology 1997; 86 (1): 10-23
37. Egan TD, Huizinga B, Gupta SK, et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology 1998; 89 (3): 562-73
38. Egan TD. Remifentanil pharmacokinetics and pharmacodynamics: a preliminary appraisal. Clin Pharmacokinet 1995; 29 (2): 80-94
39. Pavlin DJ, Coda B, Shen DD, et al. Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers. Anesthesiology 1996; 84 (1): 23-37
40. Matot I, Neely CF, Katz RY, et al. Pulmonary uptake of propofol in cats: effect of fentanyl and halothane. Anesthesiology 1993; 78 (6): 1157-65
41. Gepts E, Jonckheer K, Maes V, et al. Disposition kinetics of propofol during alfentanil anaesthesia. Anaesthesia 1988; 43 Suppl.: 8-13
42. Janicki PK, James MF, Erskine WA. Propofol inhibits enzymatic degradation of alfentanil and sufentanil by isolated liver microsomes in vitro. Br J Anaesth 1992; 68 (3): 311-2
43. Baker MT, Chadam MV, Ronnenberg Jr WC. Inhibitory effects of propofol on cytochrome P450 activities in rat hepatic microsomes. Anesth Analg 1993; 76 (4): 817-21
44. Kharasch ED, Hill HF, Eddy AC. Influence of dexmedetomidine and clonidine on human liver microsomal alfentanil metabolism. Anesthesiology 1991; 75 (3): 520-4
45. Vuyk J. Pharmacokinetic and pharmacodynamic interactions between opioids and propofol. J Clin Anesth 1997; 9 (6 Suppl.): 23-6S
46. Mertens MJ, Olofsen E, Burm AGL, et al. Mixed effects modeling of the influence on alfentanil on propofol pharmacokinetics. Anesthesiology 2004; 100: 795-805
47. Bovill JG. Adverse drug interactions in anesthesia. J Clin Anesth 1997; 9 (6 Suppl.): 3-13S
48. Minto CF, Schnider TW, Short TG, et al. Response surface model for anesthetic drug interactions. Anesthesiology 2000; 92(6): 1603-16
49. Berenbaum MC. Concepts for describing the interaction of two agents. Radiat Res 1991; 126 (2): 264-8
50. Berenbaum MC. What is synergy? Pharmacol Rev 1989; 41 (2): 93-141
51. Billard V, Moulla F, Bourgain JL, et al. Hemodynamic response to induction and intubation: propofol/fentanyl interaction. Anesthesiology 1994; 81 (6): 1384-93
52. Bouillon T, Schmidt C, Garstka G, et al. Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of alfentanil. Anesthesiology 1999; 91 (1): 144-55
53. Schüttler J, Schwilden H, Stoekel H. Pharmacokinetics as applied to total intravenous anaesthesia: practical implications. Anaesthesia 1983; 38 Suppl.: 53-6
54. Alvis JM, Reves JG, Govier AV, et al. Computer-assisted continuous infusions of fentanyl during cardiac anesthesia: comparison with a manual method. Anesthesiology 1985; 63 (1): 41-9
55. Marsh B, White M, Morton N, et al. Pharmacokinetic model driven infusion of propofol in children. Br J Anaesth 1991; 67 (1): 41-8
56. Shafer SL, Siegel LC, Cooke JE, et al. Testing computer-controlled infusion pumps by simulation. Anesthesiology 1988; 68 (2): 261-6
57. Vuyk J, Engbers FH, Burm AG, et al. Performance of computer-controlled infusion of propofol: an evaluation of five pharmacokinetic parameter sets. Anesth Analg 1995; 81 (6): 1275-82
58. Mertens MJ, Engbers FHM, Burm AGL, et al. Predictive performance of computer controlled infusion of remifentanil during propofol-remifentanil anaesthesia. Br J Anaesth 2003; 90 (2): 132-41
59. Egan TD, Minto CF, Hermann DJ, et al. Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology 1996; 84 (4): 821-33
60. Caton R. The electrical currents of the brain. BMJ 1875; II: 278
61. Gibbs F, Gibbs E, Lennox W. Effect on the electroencephalogram of certain drugs which influence nervous activity. Arch Intern Med 1937; 60: 154-66
62. Breimer LT, Burm AG, Danhof M, et al. Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. Clin Pharmacokinet 1991; 20 (6): 497-508
63. Breimer LT, Hennis PJ, Burm AG, et al. Quantification of the EEG effect of midazolam by aperiodic analysis in volunteers: pharmacokinetic/ pharmacodynamic modelling. Clin Pharmacokinet 1990; 18(3): 245-53
64. Scott JC, Cooke JE, Stanski DR. Electroencephalographic quantitation of opioid effect: comparative pharmacodynamics of fentanyl and sufentanil. Anesthesiology 1991; 74 (1): 34-42
65. Scott JC, Ponganis KV, Stanski DR. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology 1985; 62 (3): 234-41
66. Kuizenga K, Kalkman CJ, Hennis PJ. Quantitative electroencephalographic analysis of the biphasic concentration-effect relationship of propofol in surgical patients during extradural analgesia. Br J Anaesth 1998; 80 (6): 725-32
67. Rampil IJ. A primer for EEG signal processing in anesthesia. Anesthesiology 1998; 89 (4): 980-1002
68. Johansen JW, Sebel PS. Development and clinical application of electroencephalographic bispectrum monitoring. Anesthesiology 2000; 93 (5): 1336-44
69. Glass PS, Bloom M, Kearse L, et al. Bispectral analysis measures sedation and memory effects of propofol, midazolam, isoflurane, and alfentanil in healthy volunteers. Anesthesiology 1997; 86 (4): 836-47
70. Lysakowski C, Dumont L, Pellegrini M, et al. Effects of fentanyl, alfentanil, remifentanil and sufentanil on loss of consciousness and bispectral index during propofol induction of anaesthesia. Br J Anaesth 2001; 86 (4): 523-7
71. Struys MM, De Smet T, Versichelen LF, et al. Comparison of closed-loop controlled administration of propofol using Bispectral Index as the controlled variable versus 'standard practice' controlled administration. Anesthesiology 2001; 95 (1): 6-17
72. Mortier E, Struys M, De Smet T, et al. Closed-loop controlled administration of propofol using bispectral analysis. Anaesthesia 1998; 53 (8): 749-54
73. Absalom AR, Sutcliffe N, Kenny GN. Closed-loop control of anesthesia using Bispectral index: performance assessment in patients undergoing major orthopedic surgery under combined general and regional anesthesia. Anesthesiology 2002; 96 (1): 67-73
74. Thornton C, Barrowcliffe MP, Konieczko KM, et al. The auditory evoked response as an indicator of awareness. Br J Anaesth 1989; 63: 113-5
75. Schraag S, Bothner U, Gajraj RJ, et al. The performance of the electroencephalogram bispectral index and auditory evoked potential index to predict loss of consciousness during propofol infusion. Anesth Analg 1999; 89: 1311-5
76. Bonhomme V, Plourde G, Meuret P, et al. Auditory steady-state response and bispectral index for assessing level of consciousness during propofol sedation and hypnosis. Anesth Analg 2000; 91: 1398-403